Table of Contents
Chapter 1 Research Methodology
1.1 Information procurement
1.2 Information or Data Analysis
1.2.1 Market Formulation & Validation
1.3 Region Wise Market Calculation
1.3.1 Region Wise Market: Base Estimates
1.3.2 Global Market: CAGR Calculation
Chapter 2 Executive Summary
2.1 Market Snapshot
Chapter 3 Prostate Cancer Diagnostics Market Variables, Trends & Scope
3.1 Market segmentation & scope
3.1.1 Market Driver Analysis
3.1.1.1 Increasing prevalence of prostate cancer
3.1.1.2 Increasing government initiatives
3.1.1.3 Technological advancements
3.1.2 Market Restraint Analysis
3.1.2.1 High cost of diagnosis
3.2 Penetration & growth prospect mapping
3.3 Prostate Cancer Diagnostics – SWOT Analysis, By Factor (political & legal, economic and technological)
3.4 Industry Analysis – Porter’s
Chapter 4 Prostate Cancer Diagnostics Market: Type Estimates & Trend Analysis
4.1 Prostate cancer diagnostics market: Type movement analysis
4.2 Preliminary Tests
4.3 Confirmatory Tests
4.3.1. Confirmatory Tests Market Estimates & Segment Forecast, 2014 – 2025 (USD Million)
4.3.2 PCA3Test
4.3.2.1 PCA3Test Market, 2014 – 2025 (USD Million)
4.3.3 Trans-rectal ultrasound
4.3.3.1 Trans-rectal ultrasound Market, 2014 – 2025 (USD Million)
4.3.4 Biopsy
4.3.4.1 Biopsy Market, 2014 – 2025 (USD Million)
Chapter 5 Prostate Cancer Diagnostics Market: Regional Estimates & Trend Analysis, by Type
5.1 Prostate Cancer Diagnostics Market: Regional Movement Analysis
5.2 Prostate cancer diagnostics market share by region, 2015 & 2025
5.3 North America
5.3.1 North America market, 2014 – 2025 (USD Million)
5.3.2 U.S.
5.3.2.1 U.S. market, 2014 – 2025 (USD Million)
5.3.3 Canada
5.3.3.1 Canada market, 2014 – 2025 (USD Million)
5.4 Europe
5.4.1 Europe market, 2014 – 2025 (USD Million)
5.4.2 U.K.
5.4.2.1 U.K. market, 2014 – 2025 (USD Million)
5.4.3 Germany
5.4.3.1 Germany market, 2014-2025 (USD Million)
5.5 Asia Pacific
5.5.1 Asia Pacific market, 2014 – 2025 (USD Million)
5.5.2 Japan
5.5.2.1 Japan market, 2014 – 2025 (USD Million)
5.5.3 China
5.5.3.1 China market, 2014 – 2025 (USD Million)
5.6 Latin America
5.6.1 Latin America market, 2014 – 2025 (USD Million)
5.6.2 Brazil
5.6.2.1 Brazil market, 2014 – 2025 (USD Million)
5.6.3 Mexico
5.6.3.1 Mexico market, 2014 – 2025 (USD Million)
5.7 MEA
5.7.1 MEA market, 2014 – 2025 (USD Million)
5.7.2 South Africa
5.7.2.1 South Africa market, 2014 – 2025 (USD Million)
Chapter 6 Competitive Landscape
6.1 Strategy framework
6.2 Company Profiles
6.2.1 MDxHealth
6.2.1.1 Company overview
6.2.1.2 Financial performance
6.2.1.3 Product benchmarking
6.2.1.4 Strategic initiatives
6.2.2 3D Signatures
6.2.2.1 Company overview
6.2.2.2 Product benchmarking
6.2.2.3 Strategic initiatives
6.2.3 Genomic Health
6.2.3.1 Company overview
6.2.3.2 Financial Performance
6.2.3.3 Product Benchmarking
6.2.3.4 Strategic initiatives
6.2.4 Abbott
6.2.4.1 Company overview
6.2.4.2 Financial performance
6.2.4.3 Product benchmarking
6.2.5 OPKO Health, Inc.
6.2.5.1 Company overview
6.2.5.2 Financial performance
6.2.5.3 Product benchmarking
6.2.6 Siemens Healthcare GmbH
6.2.6.1 Company overview
6.2.6.2 Financial Performance
6.2.6.3 Product benchmarking
6.2.7 DiaSorin S.p.A.
6.2.7.1 Company overview
6.2.7.2 Financial performance
6.2.7.3 Product benchmarking
6.2.7.4 Strategic initiatives
6.2.8 bioMérieux SA
6.2.8.1 Company overview
6.2.8.2 Financial performance
6.2.8.3 Product benchmarking
6.2.9 F. Hoffman La Roche Ltd.
6.2.9.1 Company overview
6.2.9.2 Financial performance
6.2.9.3 Product benchmarking
6.2.9.4 Strategic initiatives
6.2.10 Beckman Coulter, Inc.
6.2.10.1 Company overview
6.2.10.2 Financial performance
6.2.10.3 Product benchmarking
6.2.11 Myriad Genetic, Inc.
6.2.11.1 Company overview
6.2.11.2 Financial performance
6.2.11.3 Product benchmarking
6.2.11.4 Strategic Initiatives
TABLE 1 North America Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
TABLE 2 U.S. Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
TABLE 3 Canada Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
TABLE 4 Europe Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
TABLE 5 Germany Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
TABLE 6 U.K. Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
TABLE 7 Asia-Pacific Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
TABLE 8 Japan Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
TABLE 9 China Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
TABLE 10 Latin America Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
TABLE 11 Brazil Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
TABLE 12 Mexico Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
TABLE 13 Middle East & Africa Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
TABLE 14 South Africa Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
List of Figures
FIG. 1 Market research process
FIG. 2 Information Procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modelling for market share assessment
FIG. 7 Market summary (USD Million), 2015
FIG. 8 Market trends & outlook
FIG. 9 Market segmentation & scope
FIG. 10 Market driver relevance analysis (Current & future impact)
FIG. 11 Market restraint relevance analysis (Current & future impact)
FIG. 12 Penetration & growth prospect mapping
FIG. 13 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 14 Porter’s Five Forces Analysis
FIG. 15 Prostate Cancer Diagnostics market: Type outlook key takeaways
FIG. 16 Prostate Cancer Diagnostics: Type Movement Analysis, USD Million
FIG. 17 Preliminary Tests Market, 2014 - 2025 (USD Million)
FIG. 18 Confirmatory Tests Market, 2014 - 2025 (USD Million)
FIG. 19 PCA3Test Market, 2014 - 2025 (USD Million)
FIG. 20 Trans-rectal ultrasound Market, 2014 - 2025 (USD Million)
FIG. 21 Biopsy Market, 2014 - 2025 (USD Million)
FIG. 22 Regional market place: Key takeaways
FIG. 23 Prostate Cancer Diagnostics Market: Regional Movement Analysis, USD Million
FIG. 24 North America market, 2014 - 2025 (USD Million)
FIG. 25 U.S. market, 2014 - 2025 (USD Million)
FIG. 26 Canada market, 2014 - 2025 (USD Million)
FIG. 27 Europe market, 2014 - 2025 (USD Million)
FIG. 28 U.K. market, 2014 - 2025 (USD Million)
FIG. 29 Germany market, 2014 - 2025 (USD Million)
FIG. 30 Asia Pacific market, 2014 - 2025 (USD Million)
FIG. 31 Japan market, 2014 - 2025 (USD Million)
FIG. 32 China market, 2014 - 2025 (USD Million)
FIG. 33 Latin America market, 2014 - 2025 (USD Million)
FIG. 34 Brazil market, 2014 - 2025 (USD Million)
FIG. 35 Mexico market, 2014 - 2025 (USD Million)
FIG. 36 MEA market, 2014 - 2025 (USD Million)
FIG. 37 South Africa market, 2014 - 2025 (USD Million)
FIG. 38 Strategy framework
【掲載企業】
MDxHealth
3D Signatures
Genomic Health
Abbott
OPKO Health, Inc.
Siemens Healthcare GmbH
DiaSorin S.p.A.
bioMérieux SA
F. Hoffman La Roche Ltd.
Beckman Coulter, Inc.
Myriad Genetic, Inc.